论文部分内容阅读
目的观察恩替卡韦结合安络化纤丸对乙肝肝硬化患者治疗的临床效果。方法 160例乙肝肝硬化患者,随机分为观察组与对照组,每组80例。对照组患者单用恩替卡韦治疗,观察组患者在对照组患者治疗基础上加用安络化纤丸治疗,对比两组肝功能改变情况、乙肝病毒的脱氧核糖核酸(HBV-DNA)阴转情况及肝纤维指标降低情况。结果治疗后,观察组患者病毒转阴率为93.47%,对照组为92.86%,比较差异无统计学意义(P>0.05)。观察组患者治疗前谷丙转氨酶(ALT)、血清透明质酸(HA)、Ⅲ型前胶原(PCⅢ)、层粘连蛋白(LN)以及门静脉内径分别为(155.2±14.0)U/L、(270.0±133.3)μg/L、(173.8±30.0)μg/L、(194.2±66.1)μg/L、(1.38±0.3)cm,治疗后分别(26.1±13.1)U/L、(183.8±32.5)μg/L、(152.0±23.0)μg/L、(104.8±52.7)μg/L以及(1.23±0.40)cm,对照组患者治疗前ALT、HA、PCⅢ、LN以及门静脉内径分别为(158.3±16.0)U/L、(279.5±131.5)μg/L、(1180.2±26.1)μg/L、(199.2±59.5)μg/L以及(1.30±0.30)cm,治疗后分别(29.1±8.7)U/L、(235.1±8.3)μg/L、(154.1±30.6)μg/L、(138.2±57.6)μg/L以及(1.20±0.30)cm,观察组患者在转氨酶降低程度、门静脉内径降低以及肝纤维指标改善均优于对照组(P<0.05)。结论使用恩替卡韦结合安络化纤丸对乙肝肝硬化患者实施治疗的临床效果显著,值得推广使用。
Objective To observe the clinical efficacy of entecavir combined with Xinluo Huaxian Pills in the treatment of hepatitis B cirrhosis patients. Methods 160 cases of hepatitis B cirrhosis patients were randomly divided into observation group and control group, 80 cases in each group. The patients in the control group were treated with entecavir alone. The patients in the observation group were treated with Anluo Huaxian Wan on the basis of the treatment of patients in the control group. The changes of liver function, hepatitis B virus DNA (DNA-DNA) Fiber indicators reduce the situation. Results After treatment, the rate of virus negative conversion in the observation group was 93.47% and that in the control group was 92.86%, with no significant difference (P> 0.05). The patients in the observation group had an average of (155.2 ± 14.0) U / L, (270.0 ± 133.3μg / L, 173.8 ± 30.0μg / L, 194.2 ± 66.1μg / L and 1.38 ± 0.3cm respectively. After treatment, they were (26.1 ± 13.1) U / L and (15.2 ± 23.0) μg / L, (10.44 ± 52.7) μg / L and (1.23 ± 0.40) cm, respectively. The mean ALT, HA, PC Ⅲ, LN and portal vein diameters before treatment in the control group were (158.3 ± 16.0) (29.1 ± 8.7) U / L, (279.5 ± 131.5) μg / L, (1180.2 ± 26.1) μg / L and (199.2 ± 59.5) μg / L and (235.1 ± 8.3) μg / L, (154.1 ± 30.6) μg / L, (138.2 ± 57.6) μg / L and (1.20 ± 0.30) cm respectively. The patients in the observation group had decreased transaminase, decreased portal vein diameter and improved hepatic fibrosis All better than the control group (P <0.05). Conclusions The clinical effect of entecavir combined with Anluo Huaxian Pill in the treatment of patients with hepatitis B cirrhosis is significant and worthy of promotion.